A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity

Locations

Germany

Start date

07/09/2026

Identifiers

Trial ID NN9487-8155,
NCT number NCT07815067,
Eudract number Not Available

Summary

The purpose of this clinical study is to test how taking zenagamtide tablets with different meal/water variations affects how much zenagamtide enters the bloodstream in people who have overweight or obesity. All participants will get zenagamtide.

Trial Overview:

Condition

Overweight

Obesity

Treatment

DRUG: Zenagamtide injection

DRUG: Zenagamtide tablet

Study type

INTERVENTIONAL

Trial duration

Sep 07 2026 - Jun 12 2028

Participants

320

Phase

Are you eligible?

Gender

Male and female

Age

18 years and older

Find out how you can participate

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.